Contract Services, Formulation and Drug Delivery

Adare Pharma Solutions Coordinating Quality with Veeva Vault Quality Suite

January 13, 2023

The Vault Quality Suite will help Adare simplify its quality operations across its sites in the United States, France, and Italy.

Societal CDMO Signs Multiple CDMO Service Agreements

October 25, 2022

Under two new agreements, Societal CDMO will offer analytical, technical transfer, formulation, manufacturing, and packaging services for novel therapeutics.

Advances in Drug Delivery and Areas for Improvement

September 02, 2022

While a variety of innovations have already impacted the drug delivery landscape, improving sustainability and having the ability to make smaller volumes of drug products still require work.

Deciding Where to Outsource in Biopharma Development and Manufacturing

August 02, 2022

Experts divulge where the industry is outsourcing most frequently, when companies should outsource more, and when performing tasks in-house might be best.

Balancing Internal Focus Against External Capabilities

May 19, 2022

Demand for outsourced services of technical R&D activities is increasing.

Fostering Orphan Drugs

May 15, 2022

CDMOs offer expertise and customization options for sponsors of orphan drugs.

Method Development in Demand

February 01, 2022

Experience is an invaluable asset for outsourcing partners, particularly as more challenging method development services are in demand.

Evolving Demands of Process Development Services

February 01, 2022

Shifting demands from industry innovators is leading to an increased need for flexible and agile outsourcing partners offering broad and integrated models.

Pharma Services Sector Poised for Continued Growth and Consolidation

August 05, 2021

The CRO market will see greater consolidation by both financial buyers looking to consolidate smaller players and larger CRO players wanting to expand into value-added specialty service areas.

SelectImmune and Lonza to Develop Immunotherapeutic Drug Candidate

June 24, 2021

The companies have entered into an agreement to develop processes for a novel immunotherapy protein.